| Affymax Provides Phase 3 Program Update for Investigational Drug, Hematide, to Treat Anemia in Chronic Renal Failure (Business Wire via Yahoo! Finance) |
|
|
PALO ALTO, Calif.----Affymax, Inc. today announced that it has notified clinical trial sites to complete treatment of patients in the Phase 3 clinical program for the investigational drug, Hematide, by the end of 2009. |